NYU Langone Health has been recognized as No. 1 in quality and safety for inpatient and ambulatory care by Vizient, Inc. On Wednesday, September 21, 2022, NYU Langone accepted the Bernard A. Birnbaum, MD, Quality Leadership Award for superior performance in patient care and the Ambulatory Quality and Accountability Award for excellence in outpatient care. Vizient is the nation’s largest healthcare performance improvement organization, and it counts among its membership 97 percent of academic medical centers in the United States.

“Outstanding quality and safety standards are the hallmarks of our institution, reflecting a culture dedicated to excellence and the best outcomes for our patients no matter where in our system they receive care,” says 

, CEO of NYU Langone Health and dean of NYU Grossman School of Medicine. “No other health system in the country has our aggregate of top quality and safety rankings from respected arbiters, including this most recent leadership designation from Vizient.”

 each placed in the top 10 of the Birnbaum Quality Leadership ranking of specialized complex care medical centers.

The Bernard A. Birnbaum, MD, Quality Leadership Award

The Bernard A. Birnbaum, MD, Quality Leadership Award ranks NYU Langone as No. 1 out of 107 comprehensive academic medical centers for excellence in delivering high-quality inpatient care in 6 domains: safety, mortality, effectiveness, efficiency, patient-centeredness, and equity.

NYU Langone consistently ranks highly in the Quality Leadership Award, but this is the first time since 2015 that the hospital has ranked at the top for both this and the Ambulatory Quality and Accountability Award.

The Ambulatory Quality and Accountability Award

The Ambulatory Quality and Accountability Award from Vizient honors NYU Langone as the No. 1 physician practice out of 55 networks. NYU Langone has been ranked among the top performers in outpatient care every year since the award was created in 2015, in recognition of its excellence in delivering high-quality care in five key domains: access to care, quality, efficiency, continuum of care, and equity. NYU Langone’s outpatient network is made up of more than 320 locations in the New York metropolitan area and in Florida.

“NYU Langone continues to expand the breadth and depth of our services so patients can access the highest-quality primary and specialty care in their own communities,” says 

, senior vice president and vice dean for clinical affairs and strategy, chief clinical officer at NYU Langone. “We are improving overall health by providing the best physicians and services in the communities we serve.”

The fully integrated NYU Langone Health hospital system has been recognized for its unparalleled quality and safety metrics by rating agencies across the board. 

 named NYU Langone the No. 1 hospital in New York and No. 3 in the nation. Earlier this year, NYU Grossman School of Medicine ranked No. 2 in the nation for research on the 2022–23 

 “Best Graduate Schools” list. The combination of the 

 rankings position NYU Langone as the top academic health system in the country devoted to patient care, education, and research.

NYU Langone has also earned an “A” top-safety rating from Leapfrog and a five-star Centers for Medicare and Medicaid Services (CMS) rating for quality, safety, and patient experience. Most recently, NYU Langone Hospital—Brooklyn received Magnet® recognition for excellence in nursing by the American Nurses Credentialing Center. Now all NYU Langone inpatient facilities have this prestigious designation, considered the gold standard for nursing.

Articles

NYU Langone Health has been recognized as No. 1 in quality and safety for inpatient and ambulatory care by Vizient, Inc. 

NYU Langone Health Receives Awards for Outstanding Quality & Safety

 a nationally renowned hematology expert, has been appointed the inaugural director of the Center for Blood Cancers at NYU Langone Health’s 

. Dr. Davies currently serves as professor in the 

 at NYU Grossman School of Medicine and director of the Clinical Myeloma Program at Perlmutter Cancer Center.

In her new role, Dr. Davies will work with established NYU Langone clinicians and scientists to enhance the new Center for Blood Cancers’clinical and translational research programs, help to recruit new basic, translational, and clinical researchers in hematological malignancies, and oversee the development of a powerful biospecimens resource to facilitate research on blood cancers across Perlmutter Cancer Center.

The Center for Blood Cancers was established, through an anonymous gift of $75 million, to enhance research and clinical efforts for all types of blood malignancies. According to the National Foundation for Cancer Research, blood cancers account for almost 10 percent of all new cancer cases in the United States each year. The most common of these—including 

—prevent the blood from performing normal functions, such as fighting off infection or preventing serious bleeding.

The Center for Blood Cancers supports new and ongoing research efforts and provides expanded educational resources for students and faculty at NYU Grossman School of Medicine. As part of the center’s mission to enhance services for patients, the recently opened state-of-the-art 

Transplantation and Cellular Therapy Center

 provides patients with a healthcare team and services dedicated to blood and marrow transplants and cell therapy. This new facility, located between 33rd and 34th Streets on 2nd Avenue, will offer outpatient transplants to appropriate patients and house a cell processing facility to enable increasing efforts in cell therapy.

“We are delighted that Dr. Davies will be leading the Center for Blood Cancers,”  

, professor in the Department of Medicine at NYU Grossman School of Medicine and section chief of hematology at Perlmutter Cancer Center, said. “Her work has been fundamental to revealing the importance of achieving complete remission in myeloma therapy, and under her leadership, the center is poised to extend treatment advances for all blood cancers.”

Dr. Davies received her medical degrees from University of Wales College of Medicine and completed her hematology specialty training in the United Kingdom. She completed fellowships at the Royal Marsden Hospital and Institute of Cancer Research, London, and the Dana-Farber Cancer Institute, Boston.

Dr. Davies joined NYU Langone in 2019 as director of the Clinical Myeloma Program at Perlmutter Cancer Center from the University of Arkansas for Medical Sciences, where she was medical director of the Myeloma Institute. Throughout her career, Dr. Davies has worked to examine potential new drugs and genetic technologies that can be used to treat myeloma more effectively. She has helped to define the role of changes in chromosomes (cytogenetics) in myeloma prognosis, which has led to the identification of myeloma subgroups that determine prognosis and promise to result in ever more personalized therapy.

At Perlmutter Cancer Center, she and her colleagues are building a clinical trial portfolio concentrating on new immunotherapy approaches, and current studies include the investigation of new immunomodulatory drugs (IMiDs), bispecific antibodies and chimeric antigen receptor (CAR)-T cell approaches. The strength of these studies is enhanced by translational work using patient samples. In collaboration with 

, professor in the Department of Medicine at NYU Grossman School of Medicine and director of multiple myeloma research at Perlmutter Cancer Center, Dr. Davies is investigating the impact of both tumor genomics and the immune microenvironment on the outcome of these immune strategies.

“I am excited to lead the Center for Blood Cancers,” Dr. Davies said. “Perlmutter Cancer Center has an outstanding team of hematologists and medical oncologists, and I am looking forward to building on this strong foundation to provide improved care for our patients.”

Faith E. Davies, MD, a nationally renowned hematology expert, has been appointed the inaugural director of the Center for Blood Cancers at NYU Langone Health’s Perlmutter Cancer Center.

Perlmutter Cancer Center at NYU Langone

Articles

NYU Langone Health Receives Awards for Outstanding Quality & Safety

Perlmutter Cancer Center Appoints Inaugural Director of Center for Blood Cancers